Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology

Novartis announced today the appointment of Bruno Strigini, as President of Novartis Oncology, effective June 1, 2014.

Mr. Strigini joins Novartis from Merck & Co where he most recently served as president for Europe/Canada, a region comprising 37 countries with over 10,000 associates. With 25 years of experience in pharmaceuticals, animal health, OTC and vaccines leading in both international and local roles, he has a global perspective on the healthcare industry, with expertise across diverse geographies, including both mature and emerging markets.

During his career, Bruno Strigini has held increasingly senior executive positions in a number of companies, such as Schering-Plough, UCB-Celltech and SmithKline Beecham. Previous roles have included President of International Operations, President of Japan and Asia-Pacific, and Senior Vice-President and Head of Global Marketing & Business Development, as well as Managing Director positions in New Zealand, the UK and Spain.

He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France. Bruno holds an MBA from IMD, Lausanne (Switzerland), a doctorate degree in pharmacy from the University of Montpellier (France), and a master’s degree in microbiology from Heriot-Watt University (UK).